Related Experiment Video
Updated: May 24, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation
Xinting Pan1, Yang Zhou1, Zhenli Li1
1The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Communications Medicine
|March 6, 2025
Summary
Des-γ-carboxy prothrombin dynamic rates effectively predict hepatocellular carcinoma recurrence risk and improve early screening. This biomarker
Area of Science:
- Hepatology and Oncology
- Biomarker Discovery and Validation
- Clinical Diagnostics
Background:
- Des-γ-carboxy prothrombin (DCP) is a recognized biomarker for hepatocellular carcinoma (HCC) diagnosis.
- Its role in evaluating HCC recurrence and patient prognosis remains largely uninvestigated.
Purpose of the Study:
- To investigate the utility of Des-γ-carboxy prothrombin (DCP) in assessing HCC recurrence and patient prognosis.
- To introduce and validate a novel metric, the DCP dynamic rate, for quantitative assessment of DCP changes.
Main Methods:
- Multicenter retrospective analysis of Exploration and Validation Cohorts (totaling 1337 patients).
- Introduction of the Des-γ-carboxy prothrombin (DCP) dynamic rate to quantify DCP changes.
- Application of DCP dynamic rates in a high-risk liver cirrhosis cohort (PreCar Cohort).
Main Results:
- Post-operative DCP decrease indicates diagnostic thresholds are unsuitable for prognosis.
- DCP dynamic rates significantly correlate with HCC recurrence risk.
- Patients with consistently positive DCP status show significantly lower recurrence-free survival.
- DCP dynamic rates identified an additional 28% of cirrhosis patients progressing to HCC.
Conclusions:
- Des-γ-carboxy prothrombin (DCP) dynamics, quantified by DCP dynamic rates, can monitor HCC recurrence.
- This novel measurement enhances prognosis prediction and improves early HCC screening sensitivity.
